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Abstract 
Background: Recovery of upper limb function is important for regaining independence after 
stroke.      
Objective: To test the effects of priming upper limb physical therapy with intermittent Theta 
Burst Stimulation (iTBS), a form of non-invasive brain stimulation. 
Methods: Eighteen adults with first-ever chronic monohemispheric subcortical stroke 
participated in this randomized, controlled, triple-blinded trial. Intervention consisted of priming 
with real or sham iTBS to the ipsilesional primary motor cortex immediately before 45 minutes 
of upper limb physical therapy, daily for ten days. Changes in upper limb function (Action 
Research Arm Test, ARAT), upper limb impairment (Fugl-Meyer Scale, FM), and corticomotor 
excitability, were assessed before, during, and immediately, one month and three months after 
the intervention. Functional magnetic resonance images were acquired before and at one month 
after the intervention. 
Results: Improvements in ARAT were observed after the intervention period when therapy was 
primed with real iTBS, but not sham, and were maintained at one month. These improvements 
were not apparent halfway through the intervention, indicating a dose effect.  Improvements in 
ARAT at one month were related to balancing of corticomotor excitability and an increase in 
ipsilesional premotor cortex activation during paretic hand grip.  
Conclusions: Two weeks of iTBS-primed therapy improves upper limb function at the chronic 
stage of stroke, for at least one month post-intervention, whereas therapy alone may not be 
sufficient to alter function. This indicates a potential role for iTBS as an adjuvant to therapy 
delivered at the chronic stage.  
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Introduction 
Upper limb (UL) impairment is common after stroke and recovery of function is important for 
regaining independence in activities of daily living.
1
 Rehabilitation of the UL involves repetitive 
motor practice to promote use-dependent neuroplasticity and functional recovery, and primarily 
occurs in the first six months after stroke.
2-4
  Whether further gains are possible beyond this time 
has been a matter of ongoing debate.
5
 Therapy may need to be primed in order to realize the 
potential for further gains in function at the chronic stage.
6
 Non-invasive brain stimulation 
techniques can be used to prime the motor cortex by promoting LTP-like plasticity
7
 and 
rendering M1 more receptive to input from other cortical areas for a greater response to 
therapy.
8-11
  
In healthy individuals the balance of excitability between the two cerebral hemispheres is 
symmetric. At the chronic stage after stroke, the ipsilesional primary motor cortex (M1) is 
typically under-excitable and interhemispheric inhibition between the hemispheres is 
asymmetric, reinforcing an imbalance in corticomotor excitability between hemispheres.
12,13
 
Better clinical outcomes for the affected hand and arm are seen when asymmetry of corticomotor 
excitability is reduced.
14
 
Non-invasive brain stimulation techniques that increase the excitability of the ipsilesional 
motor cortex may promote reorganization within ipsilesional M1 and improve the symmetry of 
corticomotor excitability between hemispheres.
9,10
 A protocol of repetitive transcranial magnetic 
stimulation (rTMS), called intermittent theta burst stimulation (iTBS), may act as a priming 
stimulus to facilitate excitability and promote use-dependent plasticity.
15,16
 Ipsilesional M1 iTBS 
followed by a single dose of UL practice at the chronic stage after stroke is more beneficial than 
UL practice alone.
17,18
 However, one study has investigated the effects of multiple sessions 
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combining iTBS with UL therapy in chronic stroke patients, with a negative result.
19
 There was 
no difference between real and sham treatment groups for any hand function outcome measure.    
The aim of this study was to examine the effects of priming UL physical therapy with iTBS 
of ipsilesional M1 in subcortical stroke patients at the chronic stage. We hypothesized that UL 
function would be improved immediately and one month after intervention in the PRIMED 
Group (receiving real iTBS and physical therapy) and exceed any benefit made by the 
CONTROL Group (receiving sham iTBS and physical therapy). We also hypothesized improved 
UL function may be associated with balancing of cortical activity toward symmetry between the 
hemispheres, assessed with neurophysiology and neuroimaging measures.  
 
 
Methods  
Participants 
Eighteen adults with UL impairment (Fugl-Meyer (FM) score > 20) at least 6 months after 
first-ever monohemispheric subcortical stroke participated in this randomized, sham-controlled, 
single-centred, triple-blinded trial. Volunteers were excluded if they had a brainstem or 
cerebellar infarction, had been diagnosed with another neurological condition,were undertaking 
any formal rehabilitation, or had contraindications to transcranial magnetic stimulation (TMS) or 
magnetic resonance imaging (MRI). They were also excluded if they were on medications that 
interfered with the interpretation of the neurophysiological results, or had significant aphasia or 
impaired cognition precluding informed consent. This study was approved by the regional ethics 
committee, and all participants gave written informed consent in accordance with the Declaration 
of Helsinki. 
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Design and procedures 
The trial design and procedures are outlined in Figure 1. Interventions and assessments are 
described below. Participants were randomly allocated to PRIMED (real iTBS + physical 
therapy) or CONTROL (sham iTBS + physical therapy) Groups after baseline assessments were 
completed. Customized software (www.rando.la) was used to allocate participants and minimize 
between-group differences in age, baseline Action Research Arm Test (ARAT) score, the 
presence of a motor evoked potential (MEP) in the paretic first dorsal interosseous (FDI) muscle 
in response to TMS of ipsilesional M1, and fractional anisotropy (FA) asymmetry in the 
posterior limbs of the internal capsules.
20
 Participants, assessors and the physiotherapist were 
blinded to group allocation. Participants were naïve to iTBS. 
* Insert Figure 1 about here * 
Intervention 
Real or sham iTBS was delivered immediately before a 45 minute session of individualized 
UL physical therapy for ten consecutive weekdays. Intermittent TBS (600 stimuli
15
) was 
delivered to ipsilesional M1 with a biphasic Rapid Stimulator (Magstim, Dyfed, UK) by an 
investigator blinded to all other aspects of data collection. Sham iTBS was delivered with a sham 
coil (Magstim, Wales, UK).  Delivery site was defined as the site on ipsilesional M1 that 
produced the largest MEP amplitude in paretic FDI using single-pulse TMS (i.e. the ‘hot-spot’).  
When no MEPs could be elicited in paretic FDI, iTBS was applied to ipsilesional M1 at the 
mirror location of the ‘hot-spot’ for contralesional M1.  Intermittent TBS intensity was set to 
90% active motor threshold (AMT) of the nonparetic FDI.  AMT was obtained as the participant 
was performing an isotonic contraction of the nonparetic FDI at around 20% maximum 
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voluntary contraction. It was defined as the minimum stimulus intensity that produced a peak-to-
peak MEP amplitude >100 μV in four of eight consecutive trials, similar to established 
guidelines.
21
 Delivery site and nonparetic AMT were determined each session. Participants 
remained at rest during and for 5 minutes after iTBS delivery.  
UL therapy was commenced five minutes after iTBS, to allow time for consolidation before 
movement.
22
 Therapy consisted of 45 minutes of UL exercises (strengthening, task-specific and 
functional tasks) delivered by an experienced neurological physiotherapist. Therapy content was 
individualised to each participant, based on the therapists own assessment.    
Assessment 
Clinical and neurophysiological assessments were completed before the intervention period 
on two occasions, separated by two weeks (Base1 and Base2). Assessments were repeated 
midway through the intervention (MID) and immediately (IMMED), one month (1M) and three 
months (3M) post-intervention. MRI studies were conducted two weeks before (MRIBASE) and 
one month after (MRIPOST) the intervention. 
The National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) 
were used to evaluate stroke severity and disability at baseline. UL function and impairment 
were evaluated with the Action Research Arm Test (ARAT
23
) and the UL component of the 
Fugl-Meyer Scale (FM
24
) respectively. Assessors were blinded to group allocation, and not 
involved in treating participants. 
TMS was used to evaluate corticomotor excitability. MEPs were recorded from FDI 
bilaterally using standard surface electromyography (EMG) techniques. Signals were amplified 
using Grass P511 amplifiers (Grass Instrument Division, Warwick, RI), band-pass filtered at 20 – 
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1000 Hz, sampled at 2 kHz and stored for subsequent analysis.  Rest motor threshold (RMT) was 
determined for each FDI, defined as the minimum stimulus intensity that produced a peak-to-
peak MEP amplitude ≥ 50 μV in four of eight consecutive trials, similar to established guidelines 
.
21
 Stimulus-response curves were constructed by recording blocks of 12 MEPs (4 – 5 seconds 
between stimuli) at intensities -5%, +5%, +15%, +25% and +35% of maximum stimulator output 
(MSO) relative to RMT, with the order of stimulus intensities randomized. Trials were rejected 
online when root mean square EMG (rmsEMG) calculated over a 100 ms window prior to the 
stimulus exceeded 10 µV. The average MEP amplitude at each stimulus intensity was calculated, 
and the slope of the linear portion of the stimulus-response curve was estimated. Slope was set to 
zero when no MEPs could be elicited. Interhemispheric balance of corticomotor excitability was 
quantified by calculating an asymmetry index from the slope value (mV/10%MSO) for the 
contralesional and ipsilesional hemisphere: CEAI = (CEcontra-CEipsi)/(CEcontra+CEipsi). The 
asymmetry index was set to 1.0 when no MEPs could be elicited from the ipsilesional M1. The 
change in corticomotor excitability asymmetry index (∆CEAI) was calculated for participants 
with MEPs in the paretic FDI. 
For neuroimaging, all T1-weighted and diffusion-weighted images were acquired with a 
Siemens 1.5 T Avanto scanner. Axial T1-weighted images were used to identify lesion location 
and had 1.0 x 1.0 x 1.0 mm voxels, a 256 mm field of view, TR=11 ms, and TE=4.94 ms.  
Diffusion-weighted images had 1.8 x 1.8 x 3.0 mm voxels, a 230 mm field of view, b=2000 
s.mm
2
, TR=6700 ms, TE=101 ms, 30 gradient directions and two averages.  All image 
processing was carried out with the Oxford FMRIB Software Library.
25
 The mean FA was 
calculated within the posterior limb of each internal capsule (PLIC) by warping a template PLIC 
volume of interest to the participants’ images.26 The structural integrity of the PLICs was 
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quantified by calculating an asymmetry index from the mean FA values: FAAI = (FAcontra–
FAipsi)/(FAcontra+FAipsi).
20,26
 
The functional MRI (FMRI) experiment was an event-related handgrip task.
27
 Blood oxygen 
level-dependent (BOLD) contrast images were acquired using a T2*-weighted single-shot 
gradient echo EPI sequence (TR=3000 ms, TE=50 ms, 3 mm isotropic voxels, axial slices, 90° 
flip angle, 64 x 64 matrix).  MRI compatible force transducers (Biopac Ltd) were placed in each 
hand, with the transducer in the paretic hand used to generate the visual feedback signal,
27
 and 
the other transducer used to monitor the presence of mirror movements.  Each scanning run 
lasted 6 min and contained 45 events separated by interstimulus intervals of 7  2 s.  Two 
scanning runs were performed with each hand for a total of 90 events per hand.  
Each event consisted of paretic hand grip to a specified level of force that was displayed 
visually using custom software and a projection system. Force targets were varied pseudo-
randomly between 10%, 15%, 25%, 30% and 35% of MVC for the paretic hand. Each target 
force was maintained for 1.7 s until a cue to ‘relax’ appeared. Rest intervals varied between 7-9 s 
and served as an implicit baseline.  
Image processing for fMRI was performed using FMRIB’s software library and FMRI expert 
analysis Tool, (FEAT V5.98).
28,29
  Images were motion and slice-time corrected, spatially 
smoothed (5 mm) and then co-registered
 
to the T1-weighted image and spatially normalized to 
the Montreal Neurological Institute (MNI) template.
30
  Each grip was modelled with the height 
(force) scaled relative to the MVC and convolved with a gamma-shaped hemodynamic response 
function, along with its time derivative.  The six motion parameters computed by MCFLIRT 
were modelled as nuisance variables, as was the handgrip force signal from the good hand (not 
  Primed therapy enhances arm function 
involved in the task). FMRI statistical analyses were determined from a contrast of handgrip 
force computed for each scan (first-level analysis).  A second-level analysis combined both scans 
in a fixed effects model for each participant at each time point (MRIBase and MRIPOST).  Both first 
and second level analyses used a corrected cluster threshold of Z>2.3 and significance threshold 
of p=0.05. For participants with a left hemisphere lesion, images were left-right flipped such that 
lesions were always on the right side to assist with group-level analyses. 
In FEAT, MRIpost - base difference images were computed from 2
nd
 level analyses, and a 2 
Group unpaired t-test was conducted at a third-level (PRIMED versus CONTROL).  An 
additional third-level analysis was conducted independent of Group to determine which brain 
areas (Post) were positively associated with ∆ARAT and ∆FM (fixed effect, single group plus 
covariate de-meaned).  Results of third-level analyses were masked using the HMAT template 
with a corrected cluster threshold of Z>2.3 and significance threshold of p=0.05.  Anatomical 
locations of activation foci were identified probabilistically using the Juelich Histological 
Atlas.
31
 
Supra-threshold voxels from Z-statistic images were identified within the Hand Motor Area 
Template,
32
 which consists of bilateral primary motor (M1) and sensory (S1) cortex, dorsal and 
ventral premotor (PMd, PMv) cortex, and  pre- and proper supplementary motor area (preSMA, 
SMA). A laterality index (LI) was calculated as: LI = (NVcontra–NVipsi)/(NVcontra+NVipsi), where 
NVcontra and  NVipsi  are the number of suprathreshold voxels within contralesional areas and  
ipsilesional areas respectively.
20,33
 ∆LI was calculated (MRIPOST –MRIBASE) such that negative 
values reflect a change toward more normal activation during the task.
27
 
Statistical analysis 
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The primary endpoint was the improvement in UL function at one month, measured with the 
ARAT. The secondary endpoints were UL impairment (FM), corticomotor excitability 
asymmetry index (CEAI) and FMRI lateralization (LI) at one month. ∆ARAT, ∆FM and ∆CEAI 
were calculated at each time-point, by subtracting the baseline from the scores at MID, IMMED, 
1M and 3M. For FMRI lateralization, ∆LI was calculated as LIPOST-LIBASE.  
Baseline, ∆ARAT and ∆FM data were analyzed using repeated measures analysis of variance 
(RM ANOVA) with the between-subject factor Group (PRIMED, CONTROL), and Time and 
Hand (when appropriate) as the within-subject factors. Kolmogoroz-Smirnov tests were used to 
confirm normality. Post hoc two-tailed independent t-tests and two-tailed one-sample t-tests were 
used to investigate significant effects. Two-tailed independent t-tests were conducted to compare 
∆LI between Groups.  
Regression analyses were used to determine associations between the change in clinical 
measures (∆ARAT and ∆FM) and the change in corticomotor excitability asymmetry (∆CEAI) 
immediately and 1M after the intervention, independent of Group. Regression analyses were also 
used to determine associations between the change in clinical measures and the change in 
lateralisation of brain activation from FMRI (∆LI) at 1M, independent of Group. For the FMRI 
data, a further analysis was conducted independent of Group to determine which brain areas at 
MRIPOST were positively associated with ∆ARAT and ∆FM at 1M.  
Baseline measures were analyzed with independent two-sided t-tests for linear continuous 
variables and two-tailed Pearson Chi-Square Tests for nominal and ordinal variables, except 
when expected cell counts were less than five, in which case two-tailed Fisher’s exact tests were 
used.  Modified Bonferroni correction was used for multiple comparisons.
34
 Significance level 
was p=0.05. 
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Results 
The PRIMED and CONTROL Groups were well-matched at baseline (Table 1). RMT was 
analyzed with an RM ANOVA, with factors Hand (Paretic, Non-paretic), Group and Time 
(Base1, Base2). RMT was higher in the paretic FDI (68 ± 6 %MSO) than the non-paretic FDI 
(40 ± 2 %MSO), as expected (F1,16=19.2, p<0.001). For each hemisphere RMT was similar 
between Groups and stable across baseline (both p>0.05), and there were no interactions (all 
p>0.4). Contralesional FDI AMT was similar for the PRIMED (51 ± 7 %MSO) and the 
CONTROL Groups (49 ± 8 %MSO) (two-tailed independent t-test, p>0.5). Intermittent TBS 
stimulation intensity was similar for the PRIMED (46 ± 6 %MSO) and CONTROL Groups (44 ± 
7 %MSO) (two-tailed independent t-test, p>0.5). Intermittent TBS protocols were well tolerated 
by participants, with no adverse effects.  There was no mortality, seizures, hospital visits or 
recurrent strokes in either group. 
* Insert Table 1 about here * 
Upper limb function 
The second baseline ARAT scores (Base2) were used to calculate ∆ARAT, as there was a 
significant effect of Time on the two baseline scores (F1,16=8.4, p=0.010). A small increase in 
mean ARAT score was seen (Base1=28.9, 95% CI 20.6 – 37.2; Base2=30.4, 95% CI 22.2 – 
38.7), probably due to increasing familiarity with the testing procedure. There was no effect or 
interaction with Group (both p>0.3). 
Upper limb function improved in the PRIMED but not CONTROL Groups immediately and 
at one month after intervention. There was a main effect of Group (F1,16=14.2, p=0.002), and no 
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effect or interaction with Time (both p>0.2) (Figure 2A). The main effect of Group arose 
because ∆ARAT was greater for the PRIMED than the CONTROL Group (PRIMED=1.9, 95% 
CI 1.1–2.8; CONTROL=-0.19, 95% CI -1.0–0.65). The increase in ARAT score was greater than 
zero immediately after the intervention (IMMED) for the PRIMED Group (mean ∆ARAT=3.2, 
t1,8=3.7, p=0.006), but not the CONTROL Group (mean ∆ARAT=-0.4, t1,8 = -1.1, p=0.312). The 
increase in ARAT was also greater than zero at the primary endpoint (1M after treatment 
concluded) for the PRIMED Group (mean ∆ARAT= 2.0, t1,8=4.0, p=0.004), but not the 
CONTROL Group (mean ∆ARAT=0.2, t1,8=0.4, p=0.719). In addition, the change in ARAT 
score was higher for the PRIMED than CONTROL Group immediately after the intervention 
(IMMED: t1,16=3.8, p=0.002), and at the primary endpoint (1M: t1,16=2.3, p=0.036). ∆ARAT did 
not differ from baseline, nor differed between groups, at the MID or 3M time-points (all p>0.1). 
* Insert Figure 2 about here * 
Upper limb impairment 
The two groups were matched at baseline for UL impairment, with no effect of Time or 
Group, and no interaction between them (all p>0.4). For consistency, FM scores at the second 
baseline were used to calculate ∆FM.  
Upper limb impairment improved in both the PRIMED and CONTROL Groups immediately 
after intervention. There were no differences between the PRIMED and CONTROL groups for 
the change in FM score, or any interaction with Time (both p>0.7). The was an effect of Time 
(F3,48=3.4, p=0.025), as FM score was greater immediately after the intervention (IMMED: 
t1,17=3.4, p=0.004), but at no other time points (all p>0.07) (Figure 2B).   
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Regression analyses 
Greater improvement in ARAT score was associated with a shift towards more balanced 
corticomotor excitability (negative ∆CEAI) 1 month after intervention. There was a weak 
negative correlation between ∆CEAI and ∆ARAT at the 1M primary endpoint (R
2
=0.269, 
p=0.028) (Figure 2C). There was no association between ∆CEAI and ∆ARAT, or ∆CEAI and 
∆FM, at the IMMED time-point (both R2<0.16, p>0.8). MEPs were present in the paretic FDI in 
13 participants. Slope was set to zero and CEAI was set to 1.0 for the remaining five participants. 
Functional MRI 
At baseline, paretic hand task performance was associated with bilateral cortical activity, 
which was more lateralised to the ipsilesional hemisphere for less impaired participants (Figure 
3). 
* Insert Figure 3 about here * 
 
At baseline, the group average activation (max Z=12.2) had peaks probabilistically located 
within the ipsilesional hemisphere across the corticospinal tract white matter (78%), primary 
motor cortex BA4a (60%) and BA4p (7%), and premotor cortex BA6 (14%) (Figure 3A). One 
month after the intervention the group average activation (max Z=16.1) had peaks similarly 
located within the ipsilesional hemisphere in the primary motor cortex BA4p (80%) and BA4a 
(46%), primary somatosensory cortex BA3b (34%) and corticospinal tract white matter (24%) 
(Figure 3B). From inspection of Figure 3(A and B), the activation spanned both hemispheres into 
all regions of the HMAT, with the peak of activation centered near the hand knob,
35
 and M1/S1 
border of the central sulcus of the ipsilesional hemisphere. Conversely in the contralesional 
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hemisphere, there was activation in the premotor, supplementary and secondary sensory regions, 
but activation was largely absent along the M1/S1 boundary and central sulcus. This indicates 
the contralesional activation pattern was unlikely to represent non-paretic hand involvement.   
Results from two participants at baseline are shown in Figure 3C and illustrate the extent to 
which activation was lateralized depending on impairment level. The red-yellow map is the task-
related activation from a participant with mild impairment and good function at baseline 
(ARAT=55; FM=54).  Activation was more lateralized and contained predominantly within the 
ipsilesional hemisphere. The blue-light blue map is from a participant with more severe 
impairment and poor function (ARAT=14; FM=26). This participant had more bilateral task-
related activation including cortical areas beyond those defined by the HMAT. 
The change in the laterality index after the intervention did not differ between the PRIMED 
and CONTROL groups (∆LI; p=0.52). When the groups were combined, there was no significant 
activation in the average pre-post and post-pre contrasts, indicating there was no consistent 
pattern of cortical reorganization across participants. 
Changes in UL function and impairment were related to two distinct patterns of activation 
post-intervention (Figure 4). Improvements in ARAT were associated with activation peaks 
(2193 voxels, max Z=6.54) in ipsilesional premotor cortex BA6 (52%) and primary motor cortex 
BA4a (4%). Improvements in FM were associated with activation peaks (1857 voxels, max 
Z=4.9) in ipsilesional primary somatosensory cortex BA1 (50%), BA2 (25%) and BA3b (19%), 
primary motor cortex BA4a (13%) and BA4p (5%) and superior parietal lobule 5L (4%). 
Activation in these areas was associated with positive linear trends in the respective clinical 
scores.   
* Insert Figure 4 about here * 
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Discussion 
Two weeks of iTBS-primed physical therapy improved UL function in people who were on 
average 20 months post-stroke. The improvement in ARAT score was modest, however it 
exceeded the intra-rater limits of agreement.
36
 Physical therapy alone was not sufficient to 
produce functional gains, possibly because the dose was inadequate. This study provides some 
insight into adequate doses of iTBS-primed therapy, as two weeks but not one week of treatment 
was required to produce improvement in UL function. Ten days of iTBS-primed therapy 
produced improvements that persisted for at least one month, but not three months. Longer 
treatment periods may produce more lasting benefits, and regular re-treatment may be needed to 
maintain these benefits long term. 
For a lower therapy dose, priming may be required to maximise recovery potential in the 
chronic phase after stroke.   Two weeks of high dose upper limb therapy such as modified 
constraint-induced movement therapy (CIMT) can produce lasting functional gains, but is only 
suitable for people with relatively mild impairment.
37
 A more recent study found that one hour of 
upper limb therapy delivered daily for two weeks did not alter motor function in people only 8 
months post-stroke.
38
 However when iTBS was delivered on the same days as therapy, motor 
function and reaction time of the paretic hand improved. The timing of iTBS relative to therapy 
was not reported in this previous study making it difficult to identify the potential mechanism 
underlying these gains. The present results indicate that iTBS may specifically prime the 
ipsilesional hemisphere in a way that increases the effectiveness of a low dose of UL therapy. 
Intermittent TBS may have created a permissive environment for cortical reorganization in 
response to therapy by facilitating cortical excitability, promoting LTP-like plasticity
7
 and 
modifying the receptiveness of M1 to input from other cortical areas.
11
 These effects may have 
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contributed to improvements in the planning, fractionation and coordination of paretic UL 
movement, reflected by an increase in ARAT score that persisted for at least one month. This 
interpretation is supported by our finding that improvement in UL function was related to 
rebalancing of M1 excitability, as hypothesized. Improvement in UL function was also related to 
an increase in ipsilesional dorsal premotor cortex activation during paretic hand grip. Dorsal 
premotor cortex is implicated in organising and selecting motor output, and through its dense 
connections with M1 is thought to make an important contribution to the recovery of motor 
function after stroke.
39
 
Upper limb impairment was reduced immediately after the intervention, regardless of whether 
participants were primed with real or sham iTBS, but this improvement did not persist one month 
later. Therapy is likely to have had both central and peripheral effects. Centrally, the increase in 
FM score was related to increased ipsilesional sensorimotor cortex activation during paretic hand 
grip, but not rebalancing of M1 excitability. The former may reflect enhanced processing of 
sensory feedback during paretic hand use. Peripheral effects such as reconditioning of muscles, 
joints and connective tissue may also contribute to reduced impairment. Although two weeks of 
therapy temporarily reduced impairment, this did not translate to improved function unless 
therapy was primed with iTBS. 
The strengths of this study are the blinding of participants, therapists and assessors, and the 
balancing of groups at baseline. The multimodal design provided some insight into the 
underlying mechanisms of the observed clinical benefits of the intervention, which was brief, 
non-invasive and well-tolerated. A potential limitation is that the resources required to conduct 
the repeated neurophysiological and neuroimaging measures constrained the study’s sample size. 
  Primed therapy enhances arm function 
However, future trials may focus on clinical outcomes, rather than underlying mechanisms, 
enabling larger sample sizes.  
In conclusion, iTBS priming of the ipsilesional hemisphere is an effective adjuvant to upper 
limb physical therapy for patients at the chronic stage. Larger gains in motor function at the 
chronic stage may be realised with primed therapy, as opposed to therapy alone. It appears that 
more than one week of primed therapy is required to produce improvements in motor function, 
and more than two weeks of primed therapy may be required to produce lasting benefits. Primed 
therapy promoted rebalancing of corticomotor excitability, and this was associated with greater 
improvements in UL function, confirming previous work with patients at the chronic stage of 
recovery. Improvements in UL function and impairment were associated with different patterns 
of cortical reorganization, and this may be a useful area of future research.  
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Table: Baseline characteristics for randomized participants.   
 PRIMED CONTROL p value 
Median age (range, years) 61 (21 – 80) 71 (38 – 79) 0.23 
Sex 3 F, 6 M 3 F, 6 M 1.00 
Lesioned hemisphere 3 L, 6 R 1 L, 8 R 0.58 
Median months post-stroke (range) 20 (6 – 72) 18 (7 – 56) 0.58 
Median NIHSS (range) 3 (0 – 4) 2 (0 – 5) 0.18 
Median mRS (range) 2 (2 – 4) 2 (1 – 4) 0.78 
Mean UL-FM (range) 38 (23 – 63) 40 (21 – 56) 0.88 
Mean ARAT (range) 31 (13 – 51) 30 (5 – 55) 0.93 
Paretic FDI MEPs 6 Y, 3 N 7 Y, 2 N  
Mean CE asymmetry (range) 0.887 (0.33 – 1.00) 0.541 (-0.16 – 1.00) 0.08 
Mean FA asymmetry (range) 0.215 (0.050 – 0.571) 0.258 (-0.033 – 0.485) 0.61 
    
 
Independent two-sided t-tests were used for linear continuous variables. Two-sided Pearson 
Chi-Square Tests were used for nominal and ordinal variables, except when expected cell 
counts were less than five, in which case two-sided Fisher’s exact tests was used. NIHSS = 
National Institutes of Health Stroke Scale. mRS = modified Rankin Scale. UL-FM = Upper 
limb Fugl-Meyer Scale. ARAT = Action Research Arm Test. FDI = First dorsal interosseous.  
MEPs = Motor evoked potentials. CE = Corticomotor excitability. FA = fractional anisotropy 
of the posterior limb of the internal capsule. 
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Figure legends:  
Figure 1. Trial profile and procedures. 
A. Trial profile. B. Trial procedures. Clinical and neurophysiological assessments were 
completed before (Base1, Base2) and during (MID) the intervention, and immediately 
(IMMED), one month (1M) and three months (3M) after the intervention. Functional magnetic 
resonance imaging was completed at baseline (MRIBASE) and one month after the intervention 
(MRIPOST). Intervention was either Real or Sham iTBS prior to 45 min upper limb therapy for 
ten consecutive weekdays.  
 
Figure 2. Upper limb function and impairment. 
A. Change in Action Research Arm Test score (∆ARAT) for the PRIMED (black bars) and 
CONTROL (light gray bars) Groups across time. There was a main effect of Group (p=0.002).  
ARAT score improved (positive ∆ARAT) for the PRIMED compared to the CONTROL Group.  
For the PRIMED Group ∆ARAT was positive immediately and one month after intervention, 
and was significantly greater than for the CONTROL Group (all p<0.04). B. Change in UL Fugl-
Meyer score (∆FM) across time (patterned bars).  There was a main effect of Time (p=0.025).  
FM score increased (positive ∆FM) compared to baseline immediately after intervention.  For 
both figures: MID = midway through intervention. IMMED = immediately after intervention. 
1M = one month after intervention. 3M = Three months after intervention. Error bars = standard 
error; ^ p<0.05, two-tailed t-test comparison with baseline. * p<0.05, ** p<0.01, two-tailed t-test 
comparison between Groups. C. Regression analysis between ∆ARAT score (positive values 
indicate improvement; negative values, deterioration) and ∆ corticomotor excitability asymmetry 
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index (CEAI) (negative values indicate less asymmetry) at one month after intervention (1M) for 
the PRIMED (black symbols) and CONTROL (light gray symbols). Data points are participants. 
 
Figure 3. Functional MRI results 
Event-related FMRI was performed for visuomotor force handgrip task performed with the 
paretic hand (n=16).  A. Group average activation at Baseline and B. Primary Endpoint. Colours 
show range above threshold (2.3) to max=17.3. The background anatomical image is the 
MNI152_1mm_brain, radiological convention (right hemisphere, image left). Transparent 
colours over frontal and parietal cortical regions outline the 12 areas of the Hand Motor Area 
Template (HMAT) used for pre-threshold masking of Z-statistics at the group level. C. 
Individual FMRI results from two participants (red = mild impairment; blue = severe 
impairment) at Baseline (overlaid on MNI template and HMAT as above). Crosshair is located at 
MNI coordinate (mm 35, -22, 57) from group peak of activation at baseline (A above). Colours 
show range above threshold (2.3) to max=10.3.  
Figure 4. Functional MRI covariate analyses. 
Group-level covariate analyses post-intervention found ∆ARAT (blue-light blue) was associated 
with increased activation in ipsilesional premotor cortex, and ∆FM (red-yellow) was associated 
with increased activation in ipsilesional sensorimotor cortex. Colours show range above 
threshold (2.3) to max=10.3.The background anatomical image is the MNI152_1mm_brain, 
radiological convention (right hemisphere, image left). Transparent colours over frontal and 
parietal cortical regions outline the 12 areas of the Hand Motor Area Template (HMAT) used for 
pre-threshold masking of Z-statistics at the group level.   
 
